Skip to main content

17-12-2020 | SABCS 2020 | Conference coverage | Video

Updated findings on low-risk MINDACT participants reported


Laura van 't Veer discusses the latest data from the MINDACT trial of adjuvant chemotherapy de-escalation in hormone receptor-positive early breast cancer and puts the results in the context of the RxPONDER and TAILORx findings.

Read transcript